<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973112</url>
  </required_header>
  <id_info>
    <org_study_id>HLX10-008-HCC201</org_study_id>
    <nct_id>NCT03973112</nct_id>
  </id_info>
  <brief_title>A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients With Disease Progression or Intolerant Toxicity After Standard Treatment</brief_title>
  <official_title>A Single-arm, Open, Multicenter, Phase II Clinical Study Evaluating the Use of HLX10 (Recombinant Anti-pd-1 Humanized Monoclonal Antibody Injection) in Combination With HLX04 (Recombinant Anti-vegf Humanized Monoclonal Antibody Injection) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients With Disease Progression or Intolerant Toxicity After Standard Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a single-arm, open, multicenter phase II clinical study.Subjects can only enter
      this study after they meet the inclusion and exclusion criteria.Into subjects will accept
      HLX10 + HLX04 intravenous infusion, every two weeks, lose treatment until clinical benefit,
      toxicity, the subjects of the resistance or the doctor decided to suspend the treatment,
      tested subjects death revocation of informed consent, subjects, subjects of pregnancy, not to
      plan or program requirement from, or management reasons, treatment for up to 2 years
      (before).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Objective response rate(assessed by independent radiological review</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Objective response rate (assessed by the investigators based on the RECISTv1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month OS rate</measure>
    <time_frame>from the date of first dose unitl the date of 12-month</time_frame>
    <description>12-month overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>from the date of first dose unitl the date of death from any cause，assessed up to 2 years</time_frame>
    <description>Overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month PFS rate</measure>
    <time_frame>the proportion of subjects who have time interval over 12 months between the first dose and disease progression or death</time_frame>
    <description>12-month progression-free survival (PFS) rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years</time_frame>
    <description>Progression-free survival (assessed by independent radiological review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years</time_frame>
    <description>Progression-free survival (assessed by the investigators based on RECIST v1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>from the date when CR or PR (whichever recorded earlier) is firstly achieved until the date when disease progression or death is firstly recorded (whichever occurs earlier),assessed up to 2 years</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>HLX10+HLX04</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX10+HLX04</intervention_name>
    <description>HLX10 developed by our company is sterile intravenous injection, with specification of 100 mg/10 mL/bottle. The main ingredient is 10.0 mg/mL of recombinant humanized anti-PD-1 monoclonal antibody. HLX04 is an anti-tumor angiogenesis drug, which is a biosimilar drug bevacizumab designed and developed by Shanghai fuhonghanlin biotechnology co., ltd. based on the protein sequence of Avastin® by Roche pharmaceutical company.</description>
    <arm_group_label>HLX10+HLX04</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who meet all of the following criteria are allowed to be enrolled into this
             study:

               -  Volunteer to participate in clinical research;To fully understand and understand
                  this study and to sign the Informed Consent Form (ICF);Willing to follow and able
                  to complete all test procedures.

               -  The age of signing ICF is ≥ 18 years old and ≤ 75 years old.

               -  Subjects with advanced hepatocellular carcinoma (HCC) diagnosed by histopathology
                  or cytology, or clinically diagnosed as meeting the criteria for hepatocellular
                  carcinoma of the American association of liver diseases (AASLD).

               -  Failure or intolerable toxicity after at least one standard first-line systemic
                  treatment for advanced hepatocellular carcinoma.Previous standard first-line
                  systemic therapy included sorafenib, renvastinib and oxaliplatin based
                  chemotherapy.

               -  Barcelona Clinic Liver Cancer (BCLC) (appendix I) stage C;BCLC stage B patients
                  who are not suitable for locoregional therapy may also be enrolled.

               -  At least one measurable lesion assessed by IRRC according to RECIST v1.1
                  (appendix ii) has not been treated locally for this lesion (e.g., radiotherapy,
                  radiofrequency ablation, TACE, ultrasound focusing knife, etc.).

               -  The end of previous systematic treatment must be ≥ 2 weeks after the first
                  medication in this study, and the treatment-related AE should be restored to the
                  level of ci -CTCAE ≤ 1 (except hair loss).

               -  Child-pugh liver function rating within 7 days before the first administration of
                  the study drug (appendix iii) : grade A and good grade B (≤ 7 points).

               -  The ECOG physical performance score (appendix iv) for the 7 days prior to the
                  first administration of the study drug was 0 or 1.

               -  Expected survival ≥ 12 weeks.

               -  Subjects of HBsAg (-) and HBcAb (-) were admitted into the group;If HBsAg (+) or
                  HBcAb (+), hbv-dna must be ≤ 500 IU/mL to be included in the group, and those
                  with elevated hbv-dna must agree to receive nucleoside anti-hepatitis b virus
                  treatment.Subjects with negative HCV antibody (-) or hcv-rna were admitted.If
                  hcv-rna is positive, subjects must have ALT and AST ≤ 3×ULN to be
                  enrolled.Subjects with co-infection of hepatitis b and c should be excluded.

               -  Major organs function normally and meet the following criteria (no blood
                  transfusion, albumin, recombinant human thrombogenin or colony stimulating factor
                  (CSF) treatment was received within 14 days prior to the first administration of
                  this study)

               -  Female subjects must meet:

        Menopause (defined as having not had menstruation for at least 1 year and having no other
        known cause other than menopause), or Surgical sterilization (removal of ovaries and/or
        uterus), or have fertility, but must meet: serum pregnancy test must be negative within 7
        days prior to first administration, and , agreed to the annual failure rate &lt; 1% of
        contraception or abstinence (avoid heterosexual intercourse) (from signed informed consent
        to test drugs at the end of the time at least 120 days) after the treatment (annual failure
        rate &lt; 1% of contraceptive methods including bilateral tubal ligation, male sterilization
        techniques, the correct use can inhibit ovulation hormonal contracepties, releasing hormone
        of intrauterine contraceptive device and copper intrauterine contraceptive device), and do
        not breastfeed.

        • Male subjects must be satisfied: agree with abstinence (avoid heterosexual intercourse)
        or contraceptive measures, the rules are as follows: spouse or partner has been pregnant
        for childbearing age women, male subjects must be at the end of the experiment during drug
        dosage and drug time at least 120 days after the treatment, keep abstinence or use condoms
        for birth control in order to prevent drug exposure in the embryo.The duration of the
        clinical study and the reliability of the subjects' preferences and daily lifestyle
        measures of abstinence should be considered.Regular abstinence (e.g., calender days,
        ovulation, basal body temperature, or post-ovulation methods) and ejaculation are not
        acceptable methods of contraception.

        Exclusion Criteria:

          -  Subjects who meet any of the following criteria are not allowed to be enrolled in this
             study:

               -  Hepatobiliary duct cell carcinoma, mixed cell carcinoma, or fibroblastic layer
                  cell carcinoma are known.

               -  Other active malignancies within 5 years prior to the first administration of the
                  study drug.Curable localized tumors, such as basal cell carcinoma of the skin,
                  squamous cell carcinoma of the skin, superficial bladder carcinoma, carcinoma in
                  situ of the prostate, cervical carcinoma in situ, and carcinoma in situ of the
                  breast, can be included in the group.

               -  People who are ready to undergo or have received organ or bone marrow
                  transplants.

               -  After appropriate intervention, uncontrollable pleural effusion, pericardial
                  effusion or ascites still need to be drained frequently (once a month or more
                  frequently).

               -  Symptomatic, untreated, or progressive central nervous system (CNS) or meningeal
                  metastasis.Asymptomatic subjects treated for CNS lesions can be enrolled if all
                  of the following criteria are met:

                    1. in addition to CNS, there must be lesions that can be measured according to
                       RECIST v1.1;

                    2. the patient had no history of intracranial or spinal bleeding;

                    3. metastatic lesions were limited to cerebellum or supratentorial areas (i.e.,
                       no mesencephalon, pons, medulla or spinal cord metastatic lesions);

                    4. there was no evidence of progress between the completion of CNS oriented
                       therapy and the start of research and treatment;

                    5. the patients did not receive stereotactic radiotherapy within 7 days before
                       the study treatment, did not receive whole-brain radiotherapy within 14 days
                       before the study treatment, and did not receive neurosurgical resection
                       within 28 days before the study treatment;

                    6. patients have no need for continuous use of glucocorticoids in the treatment
                       of CNS diseases.Stable doses of anticonvulsant therapy are permitted;

                    7. asymptomatic patients with newly detected CNS metastases during screening
                       are eligible to participate in the study after receiving radiotherapy or
                       surgical treatment, and there is no need to repeat screening of brain scan
                       results.

               -  Cerebrovascular accident, myocardial infarction, unstable angina pectoris and
                  poorly controlled arrhythmia occurred within half a year (including QTc interval
                  ≥ 450 ms for men and ≥ 470 ms for women) (QTc interval was calculated by
                  Fridericia formula).

               -  According to the New York heart association (NYHA) standard (appendix 5) levels Ⅲ
                  or Ⅳ cardiac insufficiency or heart colour to exceed examination: LVEF, left
                  ventricular ejection fraction &lt; 50%.

               -  A history of hepatic encephalopathy.

               -  According to the images, portal vein invasion, inferior vena cava or cardiac
                  involvement of HCC main portal branch (Vp4) were present.Patients with cancer
                  thrombus in main portal vein but smooth blood flow in contralateral branch can be
                  enrolled.

               -  Involving major airways, vessels, or large mediastinal mass located centrally (&lt;
                  30 mm from the crest).

               -  Human immunodeficiency virus (HIV) infection.

               -  Active tuberculosis.

               -  Patients with previous and current cases of interstitial pneumonia,
                  pneumoconiosis, radioactive pneumonia, drug-related pneumonia, and severe
                  impairment of lung function that may interfere with the detection and management
                  of suspected drug-related lung toxicity.

               -  Known activity or autoimmune disease or history.

               -  The study drug was treated with live attenuated vaccine within 28 days prior to
                  its first administration.

               -  Subjects requiring systemic treatment with corticosteroids (&gt; 10 mg/ day or
                  equivalent dose of prednisone) or other immunosuppressants within 14 days prior
                  to or during the study.In the absence of active autoimmune disease, the
                  inhalation or topical use of steroids, or adrenal hormone replacement at doses
                  less than 10 mg/ day of prednisone efficacy, is permitted.

               -  Within 14 days prior to the first administration of the study drug, any active
                  infection requiring systematic anti-infective treatment occurs.

               -  Major surgery was performed within 28 days prior to the first administration of
                  the study drug. Major surgery in this study was defined as the minimum recovery
                  time of 3 weeks after surgery before the surgery treated in this study could be
                  performed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jia Fan</last_name>
    <phone>021-64041990</phone>
    <email>fan.jia@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ethics committee of zhongshan hospital affiliated to fudan university</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia Fan</last_name>
      <phone>02164041990</phone>
      <phone_ext>02164041990</phone_ext>
      <email>fan.jia@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 2, 2019</study_first_submitted>
  <study_first_submitted_qc>June 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

